Drug companies are starting 2026 by lifting list prices on a huge slate of brand name medicines, even as the White House and ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and Novavax (NVAX) to trade lower on Tuesday, just as a major safety scare related ...

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday. “We will continue investing in vaccines because, as ...

Pfizer is reiterated as a 'Hold' due to structural challenges, despite a recent 12% total return and a compelling 6.7% dividend yield. PFE faces a significant patent cliff by 2028, high leverage, and ...

HHS Secretary Robert F. Kennedy Jr.'s vaccine advisors have set their sights on aluminum adjuvants in vaccines as part of their review of the U.S. pediatric vaccine schedule. While the concept of ...

Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.

LaMattina is the former president of Pfizer Global R&D and is currently a senior director at PureTech Health. In July 2006, The New York Times sent young reporter Alex Berenson to Pfizer to interview ...

The four vaccines are the first step in the surgeon general’s plan to end all Florida vaccine requirements. Medical personnel vaccinate students at KIPP Believe Charter School in New Orleans, Tuesday, ...

Pfizer CEO Albert Bourla called vaccine skepticism in the highest levels of the federal government “an anomaly” during an investor call on Tuesday.

Sen. Ron Johnson said in a letter Monday that he will continue to push for documents about deaths following the COVID-19 vaccine after the “blockbuster” revelation in November that the Trump ...